Nitrofurantoin resistance mechanism and fitness cost in Escherichia coli

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 3, 2008, Pages 495-503

  Sandegren, Linus ^a   Lindqvist, Anton ^a   Kahlmeter, Gunnar ^a,b   Andersson, Dan I ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b CENTRAL HOSPITAL   (Sweden)

Author keywords

Clinical isolates; Growth inhibition; Urinary tract infections

Indexed keywords

BACTERIAL DNA; NITROFURANTOIN; NITROREDUCTASE; OXYGEN; PROTEIN NFSB; PROTEIN NSFA;

AGAR MEDIUM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CELL; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BACTERIUM MUTANT; CONTROLLED STUDY; CULTURE MEDIUM; DNA SEQUENCE; ESCHERICHIA COLI; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STRAIN DIFFERENCE;

ANTI-INFECTIVE AGENTS, URINARY; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MUTATION; NITROFURANTOIN; NITROREDUCTASES; WOMEN;

EID: 49649095454     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn222     Document Type: Article

References (26)

1. Conklin JD. The pharmacokinetics of nitrofurantoin and its related bioavailability. Antibiot Chemother 1978; 25: 233-52.
2. Naber KG. Survey on antibiotic usage in the treatment of urinary tract infections. J Antimicrob Chemother 2000; 46 Suppl 1: 49-52; discussion 63-5.
3. Asnis RE. The reduction of Furacin by cell-free extracts of Furacin-resistant and parent-susceptible strains of Escherichia coli. Arch Biochem Biophys 1957; 66: 208-16.
4. Asnis RE, Cohen FB, Gots JS. Studies on bacterial resistance to Furacin. Antibiot Chemother 1952; 2: 123-9.
5. Peterson FJ, Mason RP, Hovsepian J et al. Oxygen-sensitive and -insensitive nitroreduction by Escherichia coli and rat hepatic microsomes. J Biol Chem 1979; 254: 4009-14.
6. McCalla DR, Reuvers A, Kaiser C. Mode of action of nitro-furazone. J Bacteriol 1970; 104: 1126-34.
7. Tu Y, McCalla DR. Effect of activated nitrofurans on DNA. Biochim Biophys Acta 1975; 402: 142-9.
8. Breeze AS, Obaseiki-Ebor EE. Mutations to nitrofurantoin and nitrofurazone resistance in Escherichia coli K12. J Gen Microbiol 1983; 129: 99-103.
9. Bryant DW, McCalla DR, Leeksma M et al. Type I nitroreduc-tases of Escherichia coli. Can J Microbiol 1981; 27: 81-6.
10. McCalla DR, Kaiser C, Green MH. Genetics of nitrofurazone resistance in Escherichia coli. J Bacteriol 1978; 133: 10-6.
11. McCalla DR, Olive P, Tu Y et al. Nitrofurazone-reducing enzymes in E. coli and their role in drug activation in vivo. Can J Microbiol 1975; 21: 1484-91.
12. Whiteway J, Koziarz P, Veall J et al. Oxygen-insensitive nitro-reductases: Analysis of the roles of nfsA and nfsB in development of resistance to 5-nitrofuran derivatives in Escherichia coli. J Bacteriol 1998; 180: 5529-39.
13. Kahlmeter G. The ECO.SENS Project: A prospective, multinational, multicentre epidemiological survey of the prevalence and antimicrobial susceptibility of urinary tract pathogens - interim report. J Antimicrob Chemother 2000; 46 Suppl 1: 15-22. discussion 63-5.
14. Andersson DI. The biological cost of mutational antibiotic resistance: any practical conclusions? Curr Opin Microbiol 2006; 9: 461-5.
15. Andersson DI, Levin BR. The biological cost of antibiotic resistance. Curr Opin Microbiol 1999; 2: 489-93.
16. Gordon DM, Riley MA. A theoretical and experimental analysis of bacterial growth in the bladder. Mol Microbiol 1992; 6: 555-62.
17. Lea DE, Coulson CA. The distribution of the numbers of mutants in bacterial populations. J Genet 1949; 49: 264-85.
18. Kobori T, Sasaki H, Lee WC et al. Structure and site-directed mutagenesis of a flavoprotein from Escherichia coli that reduces nitro-compounds: Alteration of pyridine nucleotide binding by a single amino acid substitution. J Biol Chem 2001; 276: 2816-23.
19. Richards WA, Riss E, Kass EH et al. Nitrofurantoin: Clinical and laboratory studies in urinary tract infections. JAMA 1955; 96 437-50.
20. Hudson RE, Bergthorsson U, Roth JR et al. Effect of chromosome location on bacterial mutation rates. Mol Biol Evol 2002; 19 85-92.
21. Breeze AS, Obaseiki-Ebor EE. Nitrofuran reductase activity in nitrofurantoin-resistant strains of Escherichia coli K12: Some with chromosomally determined resistance and others carrying R-plasmids. J Antimicrob Chemother 1983; 12: 543-7.
22. Breeze AS, Obaseiki-Ebor EE. Transferable nitrofuran resistance conferred by R-plasmids in clinical isolates of Escherichia coli. J Antimicrob Chemother 1983; 12: 459-67.
23. Rafii F, Hansen EB. Isolation of nitrofurantoin-resistant mutants of nitroreductase-producing Clostridium sp. strains from the human intestinal tract. Antimicrob Agents Chemother 1998; 42: 1121-6.
24. Sastry SS, Jayaraman R. Nitrofurantoin-resistant mutants of Escherichia coli: Isolation and mapping. Mol Gen Genet 1984; 196: 379-80.
25. Giannakopoulos X, Evangelou A, Kalfakalkou V et al. Human bladder urine oxygen content: Implications for urinary tract diseases. Int Urol Nephrol 1997; 29: 393-401.
26. Nilsson AI, Berg OG, Aspevall O et al. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob Agents Chemother 2003; 47: 2850-8.